Last update June 23, 2022
Decreased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment., is now set to Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.
Level of risk reviewed on June 23, 2022
Typical, first-generation antipsychotic. Periciazine, metabolite of propericiazine, is a phenothiazine derivative with general properties similar to those of chlorpromazine. It is used in the treatment of schizophrenia, bipolar disorder, disturbed behaviour and severe anxiety. Oral administration two times a day.
It is excreted in breast milk in a clinically insignificant amount. (Saito 2022)
There are very few bibiographical references of this product.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Parikh 2014), especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.